Thirty adults with leukemia or lymphoma transplanted with marrow or blood stem cells from 1-antigen mismatched related donors received tacrolimus and minidose methotrexate to prevent acute graft-versus-host disease (GVHD). The group had a median age of 42 years (range 18-56 years). Twenty-seven patients had advanced disease, and 13 were resistant to conventional therapy. Tacrolimus was administered at 0.03 mg/kg/day i.v. by continuous infusion from day ؊2, converted to oral at four times the i.v. dose following engraftment, and continued to day 180 post-transplant. Methotrexate 5 mg/m 2 was given i.v. on days 1, 3, 6 and 11. Mild nephrotoxicity was common before day 100; 69% of patients had a doubling of creatinine, 56% had a peak creatinine greater than 2 mg/dl, and two patients were dialyzed. Other toxicities prior to day 100 thought to be related to tacrolimus included hypertension (45%), hyperkalemia (17%), hyperglycemia (14%), seizures (13%), headache (3%) and hemolytic uremic syndrome (3%). Grades 2-4 GVHD occurred in 59% (95% CI, 38-70%), and grades 3-4 GVHD in 17% (95% CI, 1-32%). Overall survival at 1 year was 29% (95% CI, 12-45%). We conclude that tacrolimus and minidose methotrexate is active post-transplant immunosuppression for patients with 1-antigen mismatched donors. Keywords: tacrolimus; graft-versus-host disease; mismatched marrow transplantation Family members partially-matched at the major histocompatibility complex (MHC) have served as donors for marrow transplant candidates lacking an HLA-identical sibling.
match in the MHC. The incidence of grades 2-4 acute GVHD is 40-70% in 1-antigen mismatched marrow transplant recipients. [1] [2] [3] [4] [5] Factors that appear to alter the risk of GVHD include use of the combination of cyclosporine (CsA) and methotrexate (MTX) rather than MTX alone, 3 T cell depletion, 4, 6, 7 and recipient age. 3 Tacrolimus is an immunosuppressive fungal metabolite with pharmacokinetics and pharmacodynamics similar to those of CsA. 8, 9 In randomized trials, the combination of tacrolimus and standard-dose MTX was superior to CsA and MTX for prevention of acute GVHD in HLA-identical marrow transplant recipients and unrelated donor marrow transplant recipients. 10, 11 In an effort to reduce the risk of severe treatment-related mucositis, we previously evaluated a lower dose of MTX in combination with tacrolimus as GVHD prophylaxis for HLA-matched unrelated donor marrow transplant recipients; the incidence of grades 2-4 GVHD was 34%. 12 Using the same regimen, Geller et al 13 reported that 40% of unrelated donor marrow transplant recipients developed GVHD. Further, in a nonrandomized multicenter study of tacrolimus for unrelated donor marrow transplant recipients, the resulting incidence of grades 2-4 GVHD did not differ significantly between those who received standard dose MTX and those who received minidose MTX. 14 These results in unrelated donor marrow transplant recipients suggest that, when using tacrolimus, reducing the dose of MTX would not compromise the efficacy of the combination as GVHD prophylaxis for alternative donor marrow transplantation. In this report we have evaluated the use of tacrolimus and minidose MTX as GVHD prophylaxis for 1-antigen mismatched related donor marrow or blood stem cell recipients.
Materials and methods

Patients
From August 1994 to December 1997, 30 adults with related donors mismatched for HLA-A, HLA-B or HLA-DR by serologic testing underwent transplantation using tacrolimus and minidose methotrexate for prevention of acute GVHD. HLA typing was performed by standard serologic techniques, and polymerase chain reaction with sequence specific primers was used to subtype HLA-DR. 15 For the purposes of this study, a micromismatch refers to an allelic disparity identified by high resolution typing but not serologically, a minor mismatch refers to a serologically cross-reactive antigen, and a major mismatch refers to a serologically distinct antigen as defined by the Eleventh International Histocompatibility Workshop. 16 Nineteen patients had a single major mismatch at HLA-A or -B (three patients additionally had a micromismatch at HLA-DR), and 11 had a single major mismatch at HLA-DR. Patient and donor characteristics are listed in Table 1 . All patients had a hematologic malignancy, 90% had advanced disease, and 43% had not achieved a complete response with conventional chemotherapy. Treatment protocols were approved by the Institutional Review Board of the MD Anderson Cancer Center. Written informed consent was obtained from each recipient and donor. 12 Marrow was harvested and processed for ABO-incompatibility by standard measures when necessary. Blood stem cells were collected from filgrastim-mobilized donors by apheresis and cryopreserved as described. 18 One patient received an unmanipulated marrow transplant with 0.15 ϫ 10 6 CD34 ϩ cells/kg. This was considered inadequate, so he also was given a planned stem cell infusion partially depleted of CD3 cells 19 from the same donor 3 days later and is considered primarily a stem cell recipient (1.9 ϫ 10 6 CD34 ϩ cells/kg). None of the other transplants was depleted of T cells. Marrow harvests contained a median total nucleated cell (TNC) dose of 3.6 ϫ 10 
GVHD prophylaxis and treatment
Methotrexate 5 mg/m 2 i.v. was given on days 1, 3, 6 and 11. The dose was reduced or omitted for severe mucositis (oral ulceration or significant edema), reduction in creatinine clearance by more than 50%, or weight gain more than 10 kg. Tacrolimus was administered at 0.03 mg/kg/day i.v. by continuous infusion from day Ϫ2. Following engraftment when the patient was able to take medications orally, the 24-h dose of tacrolimus was converted 1 i.v.:4 p.o., given orally in a twice-daily divided dose to at least day 180 and tapered by 20% every 2 weeks thereafter. Doses were adjusted to maintain whole blood steady state or trough levels at 5-15 ng/ml. Tacrolimus was discontinued or reduced in dose when blood levels were elevated or serum creatinine increased. Patients were observed prospectively for development of acute GVHD. The diagnosis of GVHD was based on clinical evidence with histologic confirmation, 20 and GVHD was graded according to the consensus criteria. 21 Patients who developed grade 2-4 GVHD were treated initially with methylprednisolone at 0.5 mg/kg i.v. every 6 h.
Assessment of engraftment and toxicity
Neutrophil recovery was defined as the first of 3 consecutive days that the absolute neutrophil count (ANC) exceeded the target number (0.5 or 1.0 ϫ 10 9 /l), and platelet recovery was defined as the day that the platelet count exceeded the target number (20 or 50 ϫ 10 9 /l) with no platelet transfusions the following week. Marrow biopsies and aspirates were examined at 1, 3, 6, 12, 18 and 24 months after transplantation. Hematopoietic chimerism was evaluated by restriction fragment length polymorphisms at the AY-29 or YNH24 loci as described. 22 Early preparative regimen-related toxicity (RRT) was graded according to the criteria of Bearman et al. 23 Patients were monitored prospectively for study endpoints, and charts were reviewed for serious or life-threatening toxicities potentially due to the GVHD prophylaxis regimen. 24 
Statistical considerations
At the time of analysis, median time from transplantation was 27 months (range, 6-47 months). Actuarial estimates of times to engraftment, discharge, GVHD, nephrotoxicity, relapse and death were calculated according to the method of Kaplan and Meier, 25 and comparisons were made using the log-rank test. Class of MHC major mismatch and transplant cell type were tested as independent covariates in a proportional hazards model 26 for grades 2-4 GVHD. A two-sided P value Ͻ0.05 was considered significant.
Results
Engraftment
The median times to neutrophil recovery were 18 days (range, 11-33 days) after transplantation for an ANC у0.5 ϫ 10 9 /l and 18 days (range, 13-37 days) for an ANC у1.0 ϫ 10 9 /l for all patients. Neutrophil recovery was slightly earlier in marrow recipients than in stem cell recipients (median 17 vs 22 days for an ANC у0.5 ϫ 10 9 /l), but the difference was not significant.
Four patients had problems with graft failure. Two of these had primary graft rejection; one was a blood stem cell recipient who had persistent graft failure despite a second transplant, and the other was a marrow recipient who died of sepsis on day 33 without neutrophil recovery. The third patient had secondary graft failure 5 weeks post-transplant when her mediastinal lymphoma was progressing; durable engraftment was achieved after mediastinal irradiation and a second transplant. The fourth patient had poor graft function; counts improved after infusion of a CD34-selected blood stem cell boost 59 days post-transplant. Two of the patients with graft failure were mismatched with their donors at HLA-A, one at HLA-B, and the fourth at HLA-DR. Chimerism studies demonstrated full donor engraftment for the other patients tested while in remission after transplantation.
Platelet recovery occurred by day 100 in 68% of the patients. The median times to platelet recovery were 36 days (range, 14-100ϩ days) for a platelet count у20 ϫ 10 9 /l, and 65 days (range, 14-100ϩ days) for a platelet count у50 ϫ 10 9 /l. For marrow transplant recipients, the platelet count was у20 ϫ 10 9 /l at a median of 24 days and у50 ϫ 10 9 /l at a median of 40 days. Of the eight blood stem cell recipients, only three achieved platelet recovery to у20 ϫ 10 9 /l and two to у50 ϫ 10 9 /l by day 100 after transplantation.
GVHD prophylaxis compliance and toxicity to day 100
The full scheduled dose of MTX was administered to 100% of patients on day 1, 93% on day 3, 86% on day 6, and 62% on day 11. The most common reason for omitting the methotrexate was mucositis. Twenty-three (77%) patients developed grade 2 mucositis, and the remainder had grade 1 mucositis.
For patients who were converted from i.v. to oral tacrolimus, the median last i.v. dose was 50% (range, 14-156%) of the scheduled dose (0.03 mg/kg/day). The median oral dose of tacrolimus on day 100 was 35% (range, 11-125%) of the scheduled dose (0.12 mg/kg/day). Fourteen patients discontinued tacrolimus before day 100; one with altered mental status preterminally, three with renal insufficiency preterminally, four with relapse, and six at the time of death. Prior to day 100, 69% had a doubling of the serum creatinine from baseline, and 56% has a serum creatinine that exceeded 2.0 mg/dl (Figure 1 ). Two patients were dialyzed prior to day 100. A third patient was started on chronic dialysis after day 100 and is currently awaiting a renal transplant. Other adverse events potentially related to tacrolimus included hyperkalemia (serum potassium Ͼ5.5 mEq/dl) (17%), seizures (13%) and headache (3%). Of the patients who were discharged from hospital, all required magnesium replacement, 45% required treatment of hypertension, and 14% required insulin. Two patients developed hemolytic uremic syndrome, one prior to day 100 and one after day 100.
GVHD
Sixteen patients developed grades 2-4 acute GVHD. Nine had acute GVHD of the skin alone, and seven had visceral involvement. The actuarial rate of grade 2-4 GVHD was 59% (95% CI, 38-70%), and that of grade 3-4 GVHD was 17% (95% CI, 1-32%) for all patients (Figure 2 ). Five marrow and three stem cell recpients had steroid-resistant acute GVHD. For the marrow transplant recipients, grade 2-4 GVHD occurred in 47% (95% CI, 24-70%) and grade 3-4 GVHD in 10% (95% CI, 0-22%). All five evaluable blood stem cell recipients developed grades 2-4 GVHD, and two of the five had grades 3-4 GVHD. On univariate analysis, there was a trend for more grades 2-4 GVHD with blood stem cells than with marrow transplants (100% vs 47%, P ϭ 0.18), and with a major mismatch at HLA-DR in comparison to a major mismatch at HLA-A or -B (75% vs 48%, P ϭ 0.08), but there was no significant difference when GVHD was compared by donor relationship (51% with sibling donors vs 68% with nonsibling donors, P ϭ 0.67). In a proportional hazards model, there was a trend for increased risk of GVHD with an HLA-DR mismatch (P ϭ 0.054) and with a blood stem cell transplant (P ϭ 0.12). Seventeen patients survived in remission until at least 100 days after transplantation; the actuarial rate of chronic GVHD at 1 year was 86% (95% CI, 67-100%).
Transplant-related complications to day 100
Seventy-seven percent of patients were discharged from hospital, and the median time of discharge was day 29 (range days 14-54). The incidence of grades 3-4 RRT was 17%. Four patients had pulmonary hemorrhage or idiopathic pneumonitis, four had hemorrhagic cystitis, and one had liver failure due to biopsy-proven chronic active hepatitis. Three patients had altered mental status; one was thought to be due to an exacerbation of a pre-existing psychosis, and two were due to viral encephalitis. Eight patients had fungal sepsis or fungal tissue infections. The actuarial incidence of CMV infection was 20% for seropositive patients or patients with seropositive donors.
Relapse and survival
Six patients had documented relapse post-transplant. The actuarial relapse rate at 1 year was 25% (95% CI, 7-44%). Twenty-two patients have expired. The causes of death include two infection, eight GVHD and infection, three GVHD, five relapse, one RRT and three graft failure. Day-100 survival was 60% (95% CI, 42-78%), and the survival at 1 year was 29% (95% CI, 12-45%) ( Figure 3 ). Survival was higher for marrow transplant recipients than for blood stem cells transplant recipients at day 100 (68% vs 38%) and at 1 year (35% vs 13%), although the difference in survival was not significant (P ϭ 0.2).
Discussion
For patients lacking an HLA-identical sibling, 5-10% of patients will have a related donor mismatched at a single HLA locus. Although 1-antigen mismatched related donors are considered acceptable in the absence of an HLA-identical sibling, there is a clear increase in nonrelapse mortality due to GVHD even with the limited histoincompatibility. 2 While risk of acute GVHD is reduced when T cell depletion is used for these patients, T cell depletion also increases the risk of graft rejection. 4 In this study we have shown that tacrolimus and minidose MTX are effective for prevention of acute GVHD in 1-antigen mismatched marrow transplant recipients, and the incidence of primary graft rejection (7%) is no higher than reported for CsA and standard dose MTX for this population of patients. 27 We 28 and others [29] [30] [31] have reported that filgrastim-mobilized blood stem cells from HLA-identical siblings can be used for allogeneic transplantation without an increased risk of acute GVHD in comparison to marrow transplantation. By contrast, our results here suggest that there may be an increase in the risk of GVHD for 1-antigen mismatched blood stem cell transplant recipients in comparison to the marrow recipients (100% vs 47%), although the numbers of patients are too small to adequately test for significance. Russell et al 32 HTLp frequencies with increasing MHC disparity, 34, 35 and the risk of GVHD increased with higher frequencies of CTLp for alternative donor marrow transplantation. 34 Our clinical results may therefore reflect a higher anti-host CTLp dose in blood stem cells in comparison to marrow from mismatched donors. It should be noted, however, that most of the in vitro investigations have used unmobilized peripheral blood, and donor anti-host CTLp and HTLp frequencies have not been assessed in filgrastim-mobilized blood stem cell collections.
In the present study, we noted a trend for an increased risk of acute GVHD when the HLA-mismatch was at HLA-DR rather than at HLA-A or -B (75% vs 48%). Analyses published previously demonstrated no such relationship between risk of GVHD and locus of disparity for 1-antigen mismatched marrow transplantation. 1, 3, 4 One potential reason for this discrepancy is that the prior analyses included mostly patients receiving single-drug GVHD prophylaxis 1, 3 or multiple different GVHD prophylaxis regimens, 4 and our observation may be related to the GVHD prophylaxis regimen itself. For example, Anasetti et al 36 reported that when comparing the risk of GVHD using long MTX or CsA and standard MTX, the incidence of GVHD was lower with the combination regimen for class I mismatches, but there was no difference with class II mismatches. The results for CsA and standard MTX as GVHD prophylaxis for 1-antigen mismatched marrow transplantation in the modern era have not been published, so it is unclear how our experience using tacrolimus and minidose MTX compares.
With multiple options for alternative donors available, the question occasionally arises as to whether the 1-antigen mismatched donor or the matched unrelated donor should be used. Several nonrandomized comparisons have suggested that the risk of GVHD and the long-term outcome do not differ when comparing transplantation using these two types of donors. 2, 37, 38 Our results here with tacrolimus and minidose MTX for 1-antigen mismatched marrow transplantation are also similar to those of our previous experience 12 and that of Geller et al 13 using this regimen for matched unrelated donor marrow transplantation. Although these data do not support recruitment of a serologically matched unrelated donor when a related donor with a single mismatch at HLA-A or -B is available, the potential association between the increased risk of GVHD and disparity at HLA-DR that we have reported here further highlights the question about whether treatment-related morbidity and long-term outcome would be more favorable after transplantation from a molecularly matched unrelated donor or from a related donor mismatched for HLA-DR.
